MENOPAUSAL ESTROGEN AND ESTROGEN-PROGESTIN REPLACEMENT THERAPY AND RISK OF BREAST-CANCER (UNITED-STATES)

被引：130

作者：

SCHAIRER, C

BYRNE, C

KEYL, PM

BRINTON, LA

STURGEON, SR

HOOVER, RN

机构：

[1] Environmental Epidemiology Branch, National Cancer Institute, Betbesda, MD

[2] Department of Epidemiology, Johns Hopkins University, Baltimore, MD

来源：

CANCER CAUSES & CONTROL | 1994年 / 5卷 / 06期

关键词：

BREAST CANCER; ESTROGENS; HORMONE REPLACEMENT THERAPY; PROGESTINS; UNITED-STATES;

D O I：

10.1007/BF01831376

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study examines the relationship between menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer, focusing on whether associations differ according to whether the tumors are in situ or invasive. Data are from a prospective study conducted 1980-89 on 49,017 selected participants in the Breast Cancer Detection Demonstration Project, a five-year screening program conducted between 1973 and 1980 in the United States. Overall, the rate ratio for estrogen-only use compared with no-hormone use was 1.0, and that for the estrogen-progestin combination was 1.2 (95 percent confidence interval [CI] = 1.0-1.6). However, the associations differed according to whether the tumors were in situ or invasive. The rate ratios of in situ breast cancer associated with use of estrogens alone and the combination regimen were 1.4 (CI = 1.0-2.0) and 2.3 (CI = 1.3-3.9), respectively. Duration of estrogen-only use also was associated with risk of in situ tumors, with users for 10 or more years at twice the risk of nonusers (P-value for trend test = 0.02). Duration of use was not associated with risk of invasive cancer. Our results are consistent with the hypothesis that hormone replacement therapy is related to earlier-stage breast cancer; however, the possibility that the results reflect increased breast cancer surveillance among those taking hormones cannot be ruled out.

引用

页码：491 / 500

页数：10

共 38 条

[1]

Merz B., Pharmaceutical list tracks hit parade of prescriptions, Am Med News, 34, (1991)

[2]

Harris R.B., Laws A., Reddy V.M., King A., Haskell W., Are women using postmenopausal estrogen? A community survey, Am J Public Health, 80, pp. 1266-8, (1990)

[3]

Hemminki E., Kennedy D.L., Baum C., McKinlay S.M., Prescribing of non-contraceptive estrogens and progestins in the United States, 1974–86, Am J Public Health, 78, pp. 1478-81, (1988)

[4]

Kaufman D.W., Miller D.R., Rosenberg L., Et al., Non-contraceptive estrogen use and the risk of breast cancer, JAMA, 252, pp. 63-7, (1984)

[5]

Brinton L.A., Hoover R.N., Fraumeni J.F., Menopausal estrogens and breast cancer risk: an expanded case-control study, Br J Cancer, 54 a, pp. 825-32, (1986)

[6]

Wingo P.A., Layde P.M., Lee N.C., Rubin G., Ory H.W., The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy, JAMA, 257, pp. 209-15, (1987)

[7]

Ewertz M., Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark, Int J Cancer, 42, pp. 832-8, (1988)

[8]

Bergkvist L., Adami H.O., Persson I., Hoover R., Schairer C., The risk of breast cancer after estrogen and estrogen-progestin replacement, N Engl J Med, 321, pp. 293-7, (1989)

[9]

Palmer J.R., Rosenberg L., Clarke E.A., Miller D.R., Shapiro S., Breast cancer risk after estrogen replacement therapy: results from the Toronto breast cancer study, Am J Epidemiol, 134, pp. 1386-95, (1991)

[10]

Yang C.P., Daling J.R., Band P.R., Gallagher R.P., White E., Weiss N.S., Noncontraceptive hormone use and risk of breast cancer, Cancer Causes Control, 3, pp. 475-9, (1992)

← 1 2 3 4 →